PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32822558-4	2020	Other CD38 monospecific antibodies, such as isatuximab, MOR202, and TAK079, showed promising effects in clinical trials.	mor202	56-62	CD38 molecule	Homo sapiens	6-10	
29465271-5	2018	In this respect, CD38-targeting antibodies such as daratumumab, MOR202, and isatuximab, have high single agent activity in heavily pretreated MM patients by virtue of their pleiotropic mechanisms of action including Fc-dependent effector mechanisms and immunomodulatory activities.	mor202	64-70	CD38 molecule	Homo sapiens	17-21	
29756564-3	2019	RESULTS: Anti-CD38 monoclonal antibodies including daratumumab, isatuximab and MOR202 have shown outstanding results in relapsed and/or refractory multiple myeloma patients.	mor202	79-85	CD38 molecule	Homo sapiens	14-18	
26864107-4	2016	Together, this triggered the development of various therapeutic CD38 antibodies, including daratumumab, isatuximab, and MOR202.	mor202	120-126	CD38 molecule	Homo sapiens	64-68